Ann: Annual Report to shareholders, page-3

There are a bunch of options due today so it's likely those being cashed out.

I warned about this last week. If there's any positive price action it won't be this week.

Thoughts on the report so far:

Not much new information. No numbers for the concussion or FXS trials which is irritating. But the rept still says H2 2015 for both and coupled with the updates at clinicaltrials I'm prepared to be optimistic and say that these are probably doing OK.

The TBI trial has had 211 participants so that's definitely doing better and looks on track to get close to its 260 by the end of the year.

I always get annoyed that the share breakdown stops at the "100,000 and over category." When you have a billion shares on issue, I think we need to get the >1,000,000 category too (greater than 10 il gets you into top 20 country more or less).